# Orthopediatrics Corp: overview

KIDS · Nasdaq · CIK 1425450 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kids.md) · [Financials](/companies/kids/financials.md) · [Filings](/companies/kids/filings.md) · [Insiders](/companies/kids/insiders.md)

Latest reported revenue: [$70.5m](/filings/0001425450-26-000070.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001425450-26-000070).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [54.6](/filings/0001425450-25-000114.md) | [52.7 d](/filings/0001425450-26-000013.md) | [52.4](/filings/0001425450-26-000036.md) | [61.1](/filings/0001425450-26-000070.md) | [61.3](/filings/0001425450-25-000114.md) | [61.6 d](/filings/0001425450-26-000013.md) | [59.4](/filings/0001425450-26-000036.md) | [70.5](/filings/0001425450-26-000070.md) |
| Gross margin | % | [73.4%](/filings/0001425450-25-000114.md) | [67.5% d](/filings/0001425450-26-000013.md) | [73.0%](/filings/0001425450-26-000036.md) | [72.1%](/filings/0001425450-26-000070.md) | [73.9%](/filings/0001425450-25-000114.md) | [73.2% d](/filings/0001425450-26-000013.md) | [73.1%](/filings/0001425450-26-000036.md) | [74.3%](/filings/0001425450-26-000070.md) |
| Operating margin | % | [(10.2%)](/filings/0001425450-25-000114.md) | [(26.7%) d](/filings/0001425450-26-000013.md) | [(21.0%)](/filings/0001425450-26-000036.md) | [(17.4%)](/filings/0001425450-26-000070.md) | [(15.4%)](/filings/0001425450-25-000114.md) | [(13.3%) d](/filings/0001425450-26-000013.md) | [(14.0%)](/filings/0001425450-26-000036.md) | [(5.8%)](/filings/0001425450-26-000070.md) |
| Net margin | % | [(14.5%)](/filings/0001425450-25-000114.md) | [(30.5%) d](/filings/0001425450-26-000013.md) | [(20.3%)](/filings/0001425450-26-000070.md) | [(11.6%)](/filings/0001425450-26-000070.md) | [(19.2%)](/filings/0001425450-25-000114.md) | [(16.4%) d](/filings/0001425450-26-000013.md) | [(18.0%)](/filings/0001425450-26-000070.md) | [(10.2%)](/filings/0001425450-26-000070.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0001425450-25-000114.md) | not reported | [(0.46)](/filings/0001425450-26-000036.md) | [(0.30)](/filings/0001425450-26-000070.md) | [(0.50)](/filings/0001425450-25-000114.md) | not reported | [(0.45)](/filings/0001425450-26-000036.md) | [(0.30)](/filings/0001425450-26-000070.md) |
| Free cash flow | $m | [(11.7) d](/filings/0001425450-25-000114.md) | [(4.2) d](/filings/0001425450-26-000013.md) | [(8.4)](/filings/0001425450-26-000036.md) | [(13.9) d](/filings/0001425450-26-000070.md) | [(3.4) d](/filings/0001425450-25-000114.md) | [9.7 d](/filings/0001425450-26-000013.md) | [(5.0)](/filings/0001425450-26-000036.md) | [(3.1) d](/filings/0001425450-26-000070.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [98.0](/filings/0001425450-24-000013.md) | [122](/filings/0001425450-25-000015.md) | [149](/filings/0001425450-26-000013.md) | [205](/filings/0001425450-26-000013.md) | [236](/filings/0001425450-26-000013.md) |
| Gross margin | % | [74.9%](/filings/0001425450-24-000013.md) | [74.1%](/filings/0001425450-25-000015.md) | [74.8%](/filings/0001425450-26-000013.md) | [72.6%](/filings/0001425450-26-000013.md) | [73.1%](/filings/0001425450-26-000013.md) |
| Operating margin | % | [(18.4%)](/filings/0001425450-24-000013.md) | [(20.8%)](/filings/0001425450-25-000015.md) | [(18.0%)](/filings/0001425450-26-000013.md) | [(17.1%)](/filings/0001425450-26-000013.md) | [(16.6%)](/filings/0001425450-26-000013.md) |
| Net margin | % | [(16.6%)](/filings/0001425450-24-000013.md) | [1.0%](/filings/0001425450-25-000015.md) | [(14.1%)](/filings/0001425450-26-000013.md) | [(18.5%)](/filings/0001425450-26-000013.md) | [(16.8%)](/filings/0001425450-26-000013.md) |
| Diluted EPS | $ per share | [(0.84)](/filings/0001425450-24-000013.md) | [0.06](/filings/0001425450-25-000015.md) | [(0.92)](/filings/0001425450-26-000013.md) | [(1.64)](/filings/0001425450-26-000013.md) | [(1.69)](/filings/0001425450-26-000013.md) |
| Free cash flow | $m | [(21.2)](/filings/0001425450-24-000013.md) | [(31.8)](/filings/0001425450-25-000015.md) | [(43.9)](/filings/0001425450-26-000013.md) | [(41.3)](/filings/0001425450-26-000013.md) | [(16.0)](/filings/0001425450-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kids/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $32.1m | 1,678,983 |  | Added +160,965 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $24.3m | 1,272,714 |  | Added +98,668 |
| [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $21.1m | 1,100,370 |  | Unchanged |
| [Granahan Investment Management, LLC](/funds/1026710.md) | 2026-06-30 | $20.8m | 1,085,964 |  | Added +189,223 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $15.6m | 816,830 |  | Reduced −420,069 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $15.2m | 794,309 |  | Reduced −93,135 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $14.5m | 755,624 |  | Added +37,448 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $14.0m | 732,144 |  | Added +116,697 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $13.3m | 693,387 |  | Reduced −447,731 |
| [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $9.9m | 515,677 |  | Added +186,357 |

## Recent filings

[All 623 filings](/companies/kids/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 16:15 ET | [8-K](/filings/0001425450-26-000092.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425450-26-000092 |
| 2026-10-27 | 16:07 ET | [8-K](/filings/0001425450-26-000091.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001425450-26-000091 |
| 2026-09-11 | 08:44 ET | [SCHEDULE 13D/A](/filings/0001193125-26-388676.md) | Ownership report, active investor, amended | 0001193125-26-388676 |
| 2026-09-01 | 18:40 ET | [SCHEDULE 13D/A](/filings/0001193125-26-378878.md) | Ownership report, active investor, amended | 0001193125-26-378878 |
| 2026-08-05 | 13:56 ET | [10-Q](/filings/0001425450-26-000070.md) | Quarterly report, period 2026-06-30 | 0001425450-26-000070 |
| 2026-08-04 | 16:31 ET | [8-K](/filings/0001425450-26-000067.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425450-26-000067 |
| 2026-08-04 | 16:08 ET | [8-K](/filings/0001425450-26-000066.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001425450-26-000066 |
| 2026-06-04 | 16:22 ET | [8-K](/filings/0001425450-26-000041.md) | 5.07 Shareholder vote results | 0001425450-26-000041 |
| 2026-05-01 | 15:45 ET | [10-Q](/filings/0001425450-26-000036.md) | Quarterly report, period 2026-03-31 | 0001425450-26-000036 |
| 2026-04-30 | 16:12 ET | [8-K](/filings/0001425450-26-000033.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425450-26-000033 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001425450-26-000013.md), filed Mar 4, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/17cdd81f-b5eb-4dd1-9837-f8fe89345527)

## About the filer

- CIK: 1425450
- Tickers: KIDS
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: not reported
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:17 ET. No prices; not investment advice.